News
Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting
IMV Inc. (Nasdaq:IMV)(TSX:IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that translational data, including comprehensive immune
Puma Biotechnology Reports Third Quarter 2019 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for
Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report
IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update
IMV Inc. (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the third quarter
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic
Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today
Clovis Oncology Announces Third Quarter 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’ clinical development programs and regulatory and
Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will
Sangamo Therapeutics Announces New Scientific Advisory Board
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB). The SAB comprises an eclectic group of industry
Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31
Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2019 and provided a business update.
“Based on the totality
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
Epigenomics: Management steht das Wasser bis zum Hals!
Nach dem Kursdesaster vom Montag – die Aktie stürzte unter 1 Euro – sind die Verantwortlichen bei Epigenomics (WKN: A11QW5) alarmiert und beruhigen den Markt mit einer extra lancierten Pressemeldung
co.don: Einstiegschance durch Kapitalerhöhung?
Zu den größeren Verlierern am deutschen Aktienmarkt gehört heute das Papier von co.don (WKN: A1K022). So verliert die Aktie knapp -9% an Wert, weil das Unternehmen gestern Abend eine größere
Assembly Bioscience: Durchbruch in der Hepatits-Forschung?
Die Aktie des Biotechnologie-Unternehmens Assembly Bioscience (WKN: A117S1) konnte sich kürzlich innerhalb von nur zwei Tagen verdoppeln. Grund hierfür war, dass Anleger einen vermeintlichen
Biofrontera: Beruhigungstropfen vom Vorstand
Es wirkt wie ein Beruhigungstropfen für nervöse Anleger in Biofrontera-Aktien (WKN: 604611): CEO Prof. Dr. Hermann Lübbert kaufte laut offizieller Stimmrechtsmitteilung von gestern am Freitag und
4SC: Wichtig für Aktionäre!
4SC AG (WKN: A14KL7) hatte in den letzten Septembertagen wissenschaftliche Updates zu ihren beiden Medikamentenkandidaten in der klinischen Entwicklung – Resminostat und Domatinostat – bekannt
Biofrontera: Insider-Käufe nach Ameluz-Schock!
Haben Sie schon zu vermeintlichen Schnäppchenpreisen zugeschlagen und Biofrontera-Aktien (WKN: 604611) gekauft? Diese Frage kann Biofrontera-CEO Prof. Dr. Hermann Lübbert mit einem klaren ‚Ja‘
Biofrontera: Anleger zeigen sich schwer enttäuscht!
Heute Vormittag meldete die Leverkusener Biofrontera (WKN: 604611) ihre vorläufigen, natürlich noch nicht geprüften und somit nicht testierten, Geschäftszahlen für die ersten neun Monate des
Clinuvel nach Zulassung und +1.500% – das ist der Nachfolger!
Clinuvel-Aktionäre (WKN: A0JEGY) feiern die US-Zulassung des Medikaments Scenesse gegen eine seltene Hauterkrankung, die zu extremer Lichtempflichkeit führt. Die Aktie kann nun eine Kursrallye von
DGAP-News: Expedeon AG: Expedeon AG gibt Umstellung auf Namensaktien bekannt
DGAP-News: Expedeon AG: Expedeon AG announces conversion to registered shares
DGAP-News: Epigenomics AG: Ergebnisse des Mikrosimulationsmodells werden auf renommierter Health Conference präsentiert